Get the Stockscreener App
3.11
0.65%
0.02
Lipocine Inc stock is traded at $3.11, with a volume of 16,111.
It is up +0.65% in the last 24 hours and up +22.92% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$3.09
Open:
$3.06
24h Volume:
16,111
Relative Volume:
0.39
Market Cap:
$17.27M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.0197
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-5.18%
1M Performance:
+22.92%
6M Performance:
-2.81%
1Y Performance:
-36.66%
1-Day Range:
$2.98
$3.149
1-Week Range:
$2.98
$3.4499
52-Week Range:
$2.52
$5.50
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.11 | 17.16M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Can Lipocine Inc. stock sustain revenue growthJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
Will Lipocine Inc. stock outperform value stocksMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Can Lipocine Inc. stock resist sector downturnsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionEarnings Summary Report & Community Driven Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Lipocine reports positive safety review for PPD treatment in phase 3 trial - Investing.com Nigeria
Lipocine Announces Positive Interim Results for PPD Trial - TipRanks
[8-K] Lipocine Inc. Reports Material Event | LPCN SEC FilingForm 8-K - Stock Titan
Lipocine highlights promising interim safety profile in phase 3 trial of LPCN 1154 in postpartum depression (PPD) - MarketScreener
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - The Herald Journal
HC Wainwright Issues Negative Forecast for Lipocine Earnings - Defense World
Will Lipocine Inc. stock go up soonForecast Cut & Long-Term Growth Plans - newser.com
HC Wainwright Cuts Lipocine (NASDAQ:LPCN) Price Target to $7.00 - Defense World
Why analysts upgrade Lipocine Inc. stockJuly 2025 Earnings & Entry and Exit Point Strategies - newser.com
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
How Lipocine Inc. stock performs after earningsDollar Strength & Growth Oriented Trade Recommendations - newser.com
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline - Investing.com Nigeria
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline By Investing.com - Investing.com South Africa
LPCN: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Will a bounce in Lipocine Inc. offer an exitEarnings Risk Report & Weekly Watchlist for Consistent Profits - newser.com
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):